A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results. The study is the first randomized clinical trial to document expanded benefits among a particular group of prostate cancer patients in whom the disease had spread...
More...
More...